ABSTRACT: Castleman disease (CD) describes a heterogeneous group of rare and poorly understood lymphoproliferative disorders that can involve flu-like symptoms, multiple organ system dysfunction, and even death. Prior to 2012, the limited and disparate resources, including clinical data, tissue samples, and research funding, prevented the medical community from making positive strides towards understanding the pathogenesis of CD. The Castleman Disease Collaborative Network (CDCN) was created in 2012 to accelerate research and drug development for CD by facilitating global collaboration, strategically investing in high impact research, and engaging patients throughout the research process. The CDCN's global collaborative network has been crucial for accelerating the understanding of CD. Together, the CDCN has already helped establish a uniform terminology system and a new model of pathogenesis. With the CDCN's network in place and an ambitious international research agenda, further breakthroughs for CD are on the horizon. In this paper, we report three examples of how global collaboration has helped to advance CD research, which we believe can serve as models for other research networks and international investigators.
Unicentric CD is often cured with surgical intervention 2 .
Multicentric CD (MCD) is caused by excessive release of proinflammatory cytokines including interleukin-6 (IL-6)
3
.
MCD is further subclassified into Human Herpes Virus-8 (HHV-8) associated MCD (HHV-8-associated MCD) and
HHV-8 negative or idiopathic MCD (iMCD) 1 . In HHV-8-associated MCD, the inflammatory cascade is caused by HHV-8 replication in B-cells, which release IL-6 and other pro-inflammatory cytokines 4 . Treatment of HHV-8-associated MCD patients with rituximab, which depletes B-cells, is highly effective in these patients 5 . In iMCD, a similar inflammatory cascade occurs, but there is no HHV-8 and the cause of the inflammatory cascade, key immune cells, and key immune pathways remain unknown 6 . With an unknown etiology and pathogenesis, iMCD is difficult to treat, leading to an array of attempted treatments with variable success. A major breakthrough occurred in 2014 when siltuximab, a monoclonal antibody that neutralizes IL-6, became the first FDA-approved treatment for iMCD 7 . However, siltuximab only elicited a partial or complete response in 34 percent of patients in the clinical trial.
Research is urgently needed to elucidate the pathogenesis of iMCD in order to identify treatments for the two-thirds of patients who do not respond to siltuximab 7 . Like many rare diseases, there are several systemic factors that have slowed down progress for CD research and treatment. One major barrier for iMCD research was the lack of centralized clinical and research data. With no database to track treatments, physicians were left to make care decisions based on their own intuition, with little data to inform their choices 8 . Additionally, tissue samples were very difficult to locate for research as there was no centralized biorepository. The limited number of tissue samples for research has prevented investigators without access to samples from studying CD. 8 The scarcity of tissue samples also contributed to the lack of federal funding for research. Since researchers did not have enough samples to generate sufficient preliminary data, they have not been in a position to apply for competitive federal funding. In fact, to date, iMCD researchers have never received NIH grants, which are a crucial funding source that other rare diseases have successfully leveraged 8 . Finally, researchers in different parts of the world were not using common terminology systems, so it was difficult to understand how research studies could build upon one another. It was clear that building a collaborative network was urgently needed to centralize clinical data and tissue samples, promote the sharing of samples to achieve larger sample sizes and generate preliminary data for federal funding, establish a unified terminology system, and drive forward an international research agenda.
In 2012, Dr. David Fajgenbaum joined together a team of fellow physicians, researchers, and patients to create the Castleman Disease Collaborative Network (CDCN) 8 . The first phase of the CDCN was to create a collective global community that would work together in order to improve treatments and eventually cure CD 8 . Physicians and researchers from around the world were identified through PubMed searches and connected through an online discussion board and in-person meetings. An international Scientific Advisory Board (SAB) was established to prioritize research projects and set the overall direction of the organization 9 . The CDCN also supported and engaged patients and loved ones in the advancement of CD research 9 . See Figure 1 for a map demonstrating the distribution of physicians and researchers in the CDCN network from around the world today. See Figure 2 for a map demonstrating the distribution of patients in the CDCN network from around the word today. In order to investigate the hypothesis that a virus may be responsible for iMCD, the CDCN contracted with the Center for Infection and Immunity (CII) at Columbia University to perform a pathogen discovery study. Nucleic acids will be isolated from lymph nodes, the RNA pool will be reverse transcribed and PCR amplified to generate a sequencing library, and the sequencing libraries will then go through a pipeline to identify potential candidates 11 .
Unfortunately, CII would need at least 25 lymph nodes samples from a variety of disease states to perform this study, and the lymph node samples must be flash-frozen since RNA is sensitive to degradation during fixation 11 .
Lymph nodes are almost never frozen when removed clinically, and the CDCN was pessimistic about being able to identify enough samples for the study.
In response to this problem, the CDCN recognized the need for global collaboration in order to gather enough The registry will focus on enrolling patients from Europe and North America, but patients from anywhere around the world will be able to enroll as well. In Europe, 
Challenges
Global collaboration has been essential for improving the understanding and treatment of CD. Finally, the CDCN's global reach has helped to identify epidemiological and phenotypic differences and similarities in CD across regions that could never have been reviewed without the CDCN's network. Global collaboration has its challenges, but it also provides a great deal of hope for advancing understanding of CD and moving closer to a cure. We hope that the CDCN's model and these mini-case studies can be useful to other rare disease organizations to facilitate global collaboration.
